GlobeNewswire Inc.··Sanofi And RegeneronSanofi, Regeneron Win EU Nod for Dupixent in Young Children with Chronic Urticaria
Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.
SNYREGNchronic spontaneous urticariaDupixent